Effects of different fractions of whey protein on postprandial lipid and hormone responses in type 2 diabetes

Eur J Clin Nutr. 2012 Jul;66(7):799-805. doi: 10.1038/ejcn.2012.48. Epub 2012 May 16.

Abstract

Background/objectives: Exacerbated postprandial lipid responses are associated with an increased cardiovascular risk. Dietary proteins influence postprandial lipemia differently, and whey protein has a preferential lipid-lowering effect. We compared the effects of different whey protein fractions on postprandial lipid and hormone responses added to a high-fat meal in type 2 diabetic subjects.

Subjects/methods: A total of 12 type 2 diabetic subjects ingested four isocaloric test meals in randomized order. The test meals contained 100 g of butter and 45 g of carbohydrate in combination with 45 g of whey isolate (iso-meal), whey hydrolysate (hydro-meal), α-lactalbumin enhanced whey (lac-meal) or caseinoglycomacropeptide enhanced whey (CGMP-meal). Plasma concentrations of triglyceride, retinyl palmitate, free fatty acid, insulin, glucose, glucagon, glucagon-like peptide 1 and glucose-dependent insulinotropic peptide were measured before and at regular intervals until 8-h postprandially.

Results: We found no statistical significant differences between meals on our primary variable triglyceride. The retinyl palmitate response was higher after the hydro-meal than after the iso- and lac-meal in the chylomicron-rich fraction (P=0.008) while no significant differences were found in the chylomicron-poor fraction. The hydro- and iso-meal produced a higher insulin response compared with the lac- and CGMP-meal (P<0.001). Otherwise no significant differences in the hormone responses were found in the incremental area under the curve over the 480-min period.

Conclusions: A supplement of four different whey protein fractions to a fat-rich meal had similar effects on postprandial triglyceride responses in type 2 diabetic subjects. Whey isolate and whey hydrolysate caused a higher insulin response.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Area Under Curve
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / prevention & control
  • Caseins / pharmacology
  • Caseins / therapeutic use
  • Chylomicrons
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dietary Fats / adverse effects
  • Dietary Fats / blood*
  • Dietary Proteins / pharmacology
  • Dietary Proteins / therapeutic use*
  • Dietary Supplements
  • Diterpenes
  • Female
  • Glycopeptides / pharmacology
  • Glycopeptides / therapeutic use
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / etiology
  • Hyperlipidemias / prevention & control*
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use
  • Insulin / blood*
  • Lactalbumin / pharmacology
  • Lactalbumin / therapeutic use
  • Male
  • Middle Aged
  • Milk Proteins / pharmacology
  • Milk Proteins / therapeutic use*
  • Postprandial Period
  • Protein Hydrolysates / pharmacology
  • Protein Hydrolysates / therapeutic use
  • Retinyl Esters
  • Triglycerides / blood*
  • Vitamin A / analogs & derivatives
  • Vitamin A / blood
  • Whey Proteins

Substances

  • Caseins
  • Chylomicrons
  • Dietary Fats
  • Dietary Proteins
  • Diterpenes
  • Glycopeptides
  • Hypolipidemic Agents
  • Insulin
  • Milk Proteins
  • Protein Hydrolysates
  • Retinyl Esters
  • Triglycerides
  • Whey Proteins
  • kappa-casein glycomacropeptide
  • Vitamin A
  • retinol palmitate
  • Lactalbumin